Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ACADIA Pharmaceuticals Inc. (ACAD)

18.24   -0.08 (-0.44%) 03-24 16:00
Open: 18.21 Pre. Close: 18.32
High: 18.305 Low: 17.925
Volume: 1,390,019 Market Cap: 2,959(M)

Technical analysis

as of: 2023-03-24 4:23:44 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 23.78     One year: 25.54
Support: Support1: 17.92    Support2: 14.91
Resistance: Resistance1: 20.36    Resistance2: 21.87
Pivot: 19.79
Moving Average: MA(5): 18.85     MA(20): 19.93
MA(100): 17.46     MA(250): 17.37
MACD: MACD(12,26): -0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 6.1     %D(3): 12.9
RSI: RSI(14): 39.1
52-week: High: 28.05  Low: 12.23
Average Vol(K): 3-Month: 1,560 (K)  10-Days: 2,508 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ACAD ] has closed above bottom band by 3.2%. Bollinger Bands are 46% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 18.42 - 18.6 18.6 - 18.71
Low: 17.55 - 17.78 17.78 - 17.92
Close: 17.97 - 18.35 18.35 - 18.58

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Headline News

Sun, 26 Mar 2023
Analysts have given ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ... - Best Stocks

Mon, 20 Mar 2023
ACADIA Pharmaceuticals Inc (ACAD) Down 1.72% in Premarket Trading - InvestorsObserver

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3 ... - Nasdaq

Tue, 14 Mar 2023
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts ... - Benzinga

Mon, 13 Mar 2023
Is ACADIA Pharmaceuticals Inc (ACAD) Stock About to Get Hot Monday? - InvestorsObserver

Fri, 10 Mar 2023
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 162 (M)
Shares Float 120 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 97.7 (%)
Shares Short 8,040 (K)
Shares Short P.Month 8,100 (K)

Stock Financials

EPS -1.3
EPS Est Next Qtl -0.63
EPS Est This Year -2.55
EPS Est Next Year -1.97
Book Value (p.s.) 2.47
Profit Margin (%) -41.8
Operating Margin (%) -43.3
Return on Assets (ttm) -21.8
Return on Equity (ttm) -45.9
Qtrly Rev. Growth 4.4
Gross Profit (p.s.) 0.89
Sales Per Share 3.18
EBITDA (p.s.) -1.37
Qtrly Earnings Growth 0
Operating Cash Flow -114 (M)
Levered Free Cash Flow -35 (M)

Stock Valuations

PE Ratio -14.04
PEG Ratio -1.8
Price to Book value 7.38
Price to Sales 5.72
Price to Cash Flow -25.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.